3月10日 - ** 药物开发商Mineralys Therapeutics的MLYS.O股价盘前大涨50.42%至15.82美元
** MLYS称其实验药物lorundrostat达到了中期和晚期试验的主要目标 (link)
** 在晚期试验中，与安慰剂相比，Co's 药物在 6 周时将血压降低了 9.1 mmHg(mm 汞柱)
** Lorundrostat能抑制 醛固酮的产生，而醛固酮是一种能导致高血压的激素。
** 在中期试验中，经安慰剂调整后，该药可降低血压 7.9 毫米汞柱。
** 股价在过去 12 个月中下跌了 24.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.